Attenuation of angiotensin ii-induced vascular dysfunction and hypertension by overexpression of thioredoxin 2

Hypertension

Volumn 54, Issue 2, 2009, Pages 338-344

  Widder, Julian D ^a,d   Fraccarollo, Daniela ^a   Galuppo, Paolo ^a   Hansen, Jason M ^b   Jones, Dean P ^c   Ertl, Georg ^a   Bauersachs, Johann ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Allergy   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Angiotensin II; Endothelial function; Hypertension; Mitochondria; Reactive oxygen species; Thioredoxin 2

Indexed keywords

ANGIOTENSIN II; CYCLINE; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; THIOREDOXIN 2; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; C57BL 6 MOUSE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MITOCHONDRION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE MEASUREMENT; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; METABOLISM; NEWBORN; OXYGEN CONSUMPTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; REFERENCE VALUE; RISK FACTOR; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE DETERMINATION; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXYGEN CONSUMPTION; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; REFERENCE VALUES; RISK FACTORS; THIOREDOXINS; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATION;

EID: 68549101834     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.127928     Document Type: Article

References (29)

1. Lassegue B, Griendling KK. Reactive oxygen species in hypertension: an update. Am J Hypertens. 2004;17:852-860.
2. Harrison DG, Gongora MC, Guzik TJ, Widder J. Oxidative stress and hypertension. J Am Soc Hypertens. 2007;1:30-44.
3. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996;97:1916-1923.
4. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
5. Go YM, Jones DP. Redox compartmentalization in eukaryotic cells. Biochim Biophys Acta. 2008;1780:1273-1290.
6. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med. 2005;38:1278-1295.
7. Davidson SM, Duchen MR. Endothelial mitochondria: contributing to vascular function and disease. Circ Res. 2007;100:1128-1141.
8. Gao L, Laude K, Cai H. Mitochondrial pathophysiology, reactive oxygen species, and cardiovascular diseases. Vet Clin North Am Small Anim Pract. 2008;38:137-155, vi.
9. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488-496.
10. World CJ, Yamawaki H, Berk BC. Thioredoxin in the cardiovascular system. J Mol Med. 2006;84:997-1003.
11. Chen Y, Cai J, Murphy TJ, Jones DP. Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. J Biol Chem. 2002;277:33242-33248.
12. He M, Cai J, Go YM, Johnson JM, Martin WD, Hansen JM, Jones DP. Identification of thioredoxin-2 as a regulator of the mitochondrial permeability transition. Toxicol Sci. 2008;105:44-50.
13. Zhang H, Luo Y, Zhang W, He Y, Dai S, Zhang R, Huang Y, Bernatchez P, Giordano FJ, Shadel G, Sessa WC, Min W. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol. 2007;170:1108-1120.
14. Widder JD, Guzik TJ, Mueller CF, Clempus RE, Schmidt HH, Dikalov SI, Griendling KK, Jones DP, Harrison DG. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol. 2007;27:762-768.
15. Fink B, Laude K, McCann L, Doughan A, Harrison DG, Dikalov S. Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am J Physiol Cell Physiol. 2004;287:C895-C902.
16. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem. 1997;253:162-168.
17. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511-515.
18. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. Role of extracellular superoxide dismutase in hypertension. Hypertension. 2006;48:473-481.
19. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol. 2007;22:316-320.
20. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 2005;112:2677-2685.
21. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation. 2005;112:2668-2676.
22. Chalupsky K, Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2005;102:9056-9061.
23. Louhelainen M, Merasto S, Finckenberg P, Lapatto R, Cheng ZJ, Mervaala EM. Lipoic acid supplementation prevents cyclosporine-in-duced hypertension and nephrotoxicity in spontaneously hypertensive rats. J Hypertens. 2006;24:947-956.
24. Ebrahimian T, He Y, Schiffrin EL, Touyz RM. Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens. 2007;25:1263-1271.
25. Wenzel P, Mollnau H, Oelze M, Schulz E, Wickramanayake JM, Muller J, Schuhmacher S, Hortmann M, Baldus S, Gori T, Brandes RP, Munzel T, Daiber A. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal. 2008;10:1435-1447.
26. Morgan T. Renin, angiotensin, sodium and organ damage. Hypertens Res. 2003;26:349-354.
27. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296.
28. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007;49:1196-1201.
29. Ebrahimian T, Sairam MR, Schiffrin EL, Touyz RM. Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause. Am J Physiol Heart Circ Physiol. 2008;295: H1481-H1488.